Trial Profile
A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Neladenoson bialanate (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms PANACHE
- Sponsors Bayer
- 04 Jun 2019 Results published in the JAMA: the Journal of the American Medical Association
- 10 May 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 17 Sep 2018 Trial design published in the European Journal of Heart Failure.